Merck's Breakthrough in Treating Pulmonary Arterial Hypertension

Merck has achieved significant progress with FDA approval for a novel drug targeting pulmonary arterial hypertension, a devastating and rare disease primarily affecting women aged 30 to 60 with high mortality rates. The newly approved biologic medication called Winrever offers a unique mechanism of action by potentially remodeling blood vessels in the lungs, addressing the thickening and narrowing caused by PAH. Administered via a subcutaneous injection every three weeks, the drug signifies a crucial advancement in Merck's cardiovascular and metabolic portfolio, showcasing the company's commitment to diversification beyond oncology and vaccines.